DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

Information source: OHSU Knight Cancer Institute
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cancer

Intervention: protein expression analysis (Genetic); immunohistochemistry staining method (Other); laboratory biomarker analysis (Other); biopsy (Procedure)

Phase: N/A

Status: Terminated

Sponsored by: OHSU Knight Cancer Institute

Official(s) and/or principal investigator(s):
John T. Vetto, MD, FACS, Principal Investigator, Affiliation: OHSU Knight Cancer Institute

Summary

RATIONALE: Studying protein expression in sentinel lymph node tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help the study of cancer in the future. PURPOSE: This laboratory study is evaluating OX-40 protein expression in the sentinel lymph nodes of patients with cancer.

Clinical Details

Official title: Study of The Examination of Sentinel Lymph Nodes for OX-40 Expression in Patients With Cancer

Study design: Observational Model: Cohort, Time Perspective: Retrospective

Primary outcome:

OX-40 expression

Disease-free survival

Detailed description: OBJECTIVES:

- Determine the qualitative and quantitative expression of OX-40 and related markers in

sentinel lymph nodes previously removed from patients with cancer.

- Determine the qualitative and quantitative expression of OX-40 and related markers in

sentinel lymph nodes freshly removed from patients with cancer.

- Correlate the expression of OX-40 and related markers in sentinel lymph node tissue

with expression in nonsentinel tissue from primary tumors and nonsentinel lymph nodes, tumor stage, and patient outcomes. OUTLINE: Sections of primary tumors, nonsentinel lymph nodes, and sentinel lymph nodes will be analyzed for expression of OX-40 by immunohistochemistry. Sections of negative (no tumor metastases) lymph nodes will be used as internal controls. Fresh tissue and blood will be tested for marker analysis and in vitro assays of immune function. PROJECTED ACCRUAL: A total of 100 specimens from sentinel lymph nodes previously removed from cancer patients and 100 specimens from sentinel lymph nodes freshly removed from cancer patients will be accrued for this study.

Eligibility

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed cancer, including, but not limited to, the

following:

- Melanoma

- Breast cancer

- Invasive squamous cell cancer

- Other cancers for which patients underwent or will undergo the following:

- Adequate archived paraffin-embedded tissue for making slides for

immunostaining

- Adequate freshly removed sentinel lymph node (and primary tumor, if

available) tissue for laboratory assays

- Clinical data and date of last follow-up on tumor stage and status must be available

- Hormone receptor status not specified

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- Not specified

Locations and Contacts

OHSU Knight Cancer Institute, Portland, Oregon 97239-3098, United States
Additional Information

Starting date: April 2005
Last updated: May 24, 2012

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017